A federal appeals court ruled in AbbVie’s favor on Monday, upholding an Illinois court’s decision to dismiss allegations that the pharma giant created an unlawful “patent thicket” around its blockbuster drug Humira.
Since its first approval in rheumatoid arthritis back in 2002, Humira has become one of the industry’s top...
